Noninvasive paternal exclusion testing for cystic fibrosis in the first five to eight weeks of gestation

Specific PHGKB|HLBS|PHGKB

What's New

Last Posted: Nov 01, 2018

---

• Noninvasive paternal exclusion testing for cystic fibrosis in the first five to eight weeks of gestation.  
  Zeevi David A et al. Scientific reports 2018 Oct 8(1) 15941
• The prevalence, clinical status and genotype of cystic fibrosis patients living in Cuba using national registry data.  
  Rodríguez-Calá Fidel et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Oct
• [Neonatal screening for cystic fibrosis : towards a national implementation in Belgium in 2019].  
  Boboli H et al. Revue medicale de Liege 2018 Oct 73(10) 497-501
• Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis.  
  Smith Daniel J et al. Gene 2018 Oct 68312-17
• Triple CFTR Modulator Therapy for Cystic Fibrosis.  
  Holguin Fernando et al. The New England journal of medicine 2018 Oct
• VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.  
  Keating Dominic et al. The New England journal of medicine 2018 Oct
• [Rare diseases in post-genomic era.]  
  Pulciani Simonetta et al. Recenti progressi in medicina 108(7) 307-315
• ETHICS EVALUATION REVEALING DECISION-MAKER MOTIVES: A CASE OF NEONATAL SCREENING.  
  Raimond Véronique et al. International journal of technology assessment in health care 2018 Jan 34(2) 189-195
• New therapies pack a triple-drug punch to treat cystic fibrosis  
  A Cunningham, Science News, October 19, 2018
• VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles  
  D Keating et al, NEJM, October 18, 2018